Tvardi Therapeutics (TVRD) Operating Leases (2019 - 2026)

Tvardi Therapeutics (TVRD) posted Operating Leases of $54000.0 for Q1 2026, down 36.47% sequentially from $85000.0 in Q4 2025.

Tvardi Therapeutics (TVRD) Operating Leases (2019 - 2026) Analysis & Trends

Tvardi Therapeutics has reported Operating Leases for 8 years, with the latest figure at $54000.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $54000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54000.0 (changed N/A YoY) and the FY2025 annual result came in at $85000.0, down 57.71% from the prior year.
Operating Leases declined to $54000.0 in Q1 2026 per TVRD's latest filing, from $85000.0 in the prior quarter.
Over five years, Operating Leases peaked at $7.3 million in Q2 2024 and troughed at $54000.0 in Q1 2026.
A 5-year average of $2.5 million and a median of $740000.0 in 2022 frame the typical range for Operating Leases.
The sharpest annual moves came in 2023 and 2025: Operating Leases surged 1271.23% in 2023, then sank 98.02% in 2025.
Over 5 years, Operating Leases stood at $497000.0 in 2022, then jumped by 1124.95% to $6.1 million in 2023, then plunged by 96.7% to $201000.0 in 2024, then sank by 57.71% to $85000.0 in 2025, then plunged by 36.47% to $54000.0 in 2026.
According to Business Quant data, Operating Leases over the past three periods registered $54000.0, $85000.0, and $115000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Tvardi Therapeutics	17.36 Mn	17.36 Mn	-

Download Data